Chun-Xue Cui1, Jing-Na Deng2, Li Yan3, Yu-Ying Liu4, Jing-Yu Fan5, Hong-Na Mu6, Hao-Yu Sun7, Ying-Hong Wang8, Jing-Yan Han9. 1. Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Statis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. Electronic address: zhao837176309@163.com. 2. Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Statis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. Electronic address: Jingnadeng12@163.com. 3. Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Statis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. Electronic address: Lily750957@163.com. 4. Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Statis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. Electronic address: yuyingliu903@126.com. 5. Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Statis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. Electronic address: jingyuf@sina.cn. 6. Department of Pharmacology, School of Basic Medical Sciences Peking University, Beijing 100191, China. Electronic address: hongnamu@sina.com. 7. Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Statis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. Electronic address: Haoyu720@126.com. 8. State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address: wyh@imm.ac.cn. 9. Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing 100191, China; Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China; Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China; Key Laboratory of Statis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing 100191, China. Electronic address: hanjingyan@bjmu.edu.cn.
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE: Silibinin Capsules (SC) is a silybin-phospholipid complex with silybin as the bioactive component. Silybin accounts for 50-70% of the seed extract of Silybum marianum (L.) Gaertn.. As a traditional medicine, silybin has been used for treatment of liver diseases and is known to provide a wide range of hepatoprotective effects. AIM OF THE STUDY: High fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) is a worldwide health problem. This study was to investigate the role of SC in NAFLD with focusing on its underlying mechanism and likely target. MATERIALS AND METHODS: Male hamsters (Cricetidae) received HFD for 10 weeks to establish NAFLD model. NAFLD was assessed by biochemical assays, histology and immunohistochemistry. Proton nuclear magnetic resonance spectroscopy and western blot were conducted to gain insight into the mechanism. RESULTS: Hamsters fed HFD for 10 weeks developed fatty liver accompanying with increased triglyceride (TG) accumulation, enhancing de novo lipogenesis, increase in fatty acid (FA) uptake and reducing FA oxidation and TG lipolysis, as well as a decrease in the expression of phospho-adenosine monophosphate activated protein kinase α (p-AMPKα) and Sirt 1. SC treatment at 50mg/kg silybin and 100mg/kg silybin for 8 weeks protected hamsters from development of fatty liver, reducing de novo lipogenesis and increasing FA oxidation and p-AMPKα expression, while having no effect on FA uptake and TG lipolysis. CONCLUSIONS: SC protected against NAFLD in hamsters by inhibition of de novo lipogenesis and promotion of FA oxidation, which was likely mediated by activation of AMPKα.
ETHNOPHARMACOLOGICAL RELEVANCE: Silibinin Capsules (SC) is a silybin-phospholipid complex with silybin as the bioactive component. Silybin accounts for 50-70% of the seed extract of Silybum marianum (L.) Gaertn.. As a traditional medicine, silybin has been used for treatment of liver diseases and is known to provide a wide range of hepatoprotective effects. AIM OF THE STUDY: High fat diet (HFD)-induced nonalcoholic fatty liver disease (NAFLD) is a worldwide health problem. This study was to investigate the role of SC in NAFLD with focusing on its underlying mechanism and likely target. MATERIALS AND METHODS: Male hamsters (Cricetidae) received HFD for 10 weeks to establish NAFLD model. NAFLD was assessed by biochemical assays, histology and immunohistochemistry. Proton nuclear magnetic resonance spectroscopy and western blot were conducted to gain insight into the mechanism. RESULTS: Hamsters fed HFD for 10 weeks developed fatty liver accompanying with increased triglyceride (TG) accumulation, enhancing de novo lipogenesis, increase in fatty acid (FA) uptake and reducing FA oxidation and TG lipolysis, as well as a decrease in the expression of phospho-adenosine monophosphate activated protein kinase α (p-AMPKα) and Sirt 1. SC treatment at 50mg/kg silybin and 100mg/kg silybin for 8 weeks protected hamsters from development of fatty liver, reducing de novo lipogenesis and increasing FA oxidation and p-AMPKα expression, while having no effect on FA uptake and TG lipolysis. CONCLUSIONS: SC protected against NAFLD in hamsters by inhibition of de novo lipogenesis and promotion of FA oxidation, which was likely mediated by activation of AMPKα.
Authors: Lidiane B Muniz; Aline M Alves-Santos; Fabricio Camargo; Danieli Brolo Martins; Mara Rubia N Celes; Maria Margareth V Naves Journal: Arq Bras Cardiol Date: 2019-11 Impact factor: 2.000
Authors: Małgorzata Moszak; Monika Szulińska; Marta Walczak-Gałęzewska; Paweł Bogdański Journal: Int J Environ Res Public Health Date: 2021-02-08 Impact factor: 3.390